NCT02223000View on ClinicalTrials.gov

Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 31, 1998

Primary Completion Date

July 31, 1998

Conditions
Healthy
Interventions
DRUG

BIBV 308 SE solution

DRUG

BIBV 308 SE capsule 1

DRUG

BIBV 308 SE capsule 2

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY